Tags

Type your tag names separated by a space and hit enter

Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.
CNS Spectr 2008; 13(5):393-403CS

Abstract

Pain, spasticity, tremor, spasms, poor sleep quality, and bladder and bowel dysfunction, among other symptoms, contribute significantly to the disability and impaired quality of life of many patients with multiple sclerosis (MS). Motor symptoms referable to the basal ganglia, especially paroxysmal dystonia, occur rarely and contribute to the experience of distress. A substantial percentage of patients with MS report subjective benefit from what is often illicit abuse of extracts of the Cannabis sativa plant; the main cannabinoids include delta-9-tetrahydrocannabinol (delta9-THC) and cannabidiol. Clinical trials of cannabis plant extracts and synthetic delta9-THC provide support for therapeutic benefit on at least some patient self-report measures. An illustrative case is presented of a 52-year-old woman with MS, paroxysmal dystonia, complex vocal tics, and marijuana dependence. The patient was started on an empirical trial of dronabinol, an encapsulated form of synthetic delta9-THC that is usually prescribed as an adjunctive medication for patients undergoing cancer chemotherapy. The patient reported a dramatic reduction of craving and illicit use; she did not experience the "high" on the prescribed medication. She also reported an improvement in the quality of her sleep with diminished awakenings during the night, decreased vocalizations, and the tension associated with their emission, decreased anxiety and a decreased frequency of paroxysmal dystonia.

Authors+Show Affiliations

Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, DC, USA. stephen.deutsch@med.va.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18496477

Citation

Deutsch, Stephen I., et al. "Current Status of Cannabis Treatment of Multiple Sclerosis With an Illustrative Case Presentation of a Patient With MS, Complex Vocal Tics, Paroxysmal Dystonia, and Marijuana Dependence Treated With Dronabinol." CNS Spectrums, vol. 13, no. 5, 2008, pp. 393-403.
Deutsch SI, Rosse RB, Connor JM, et al. Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol. CNS Spectr. 2008;13(5):393-403.
Deutsch, S. I., Rosse, R. B., Connor, J. M., Burket, J. A., Murphy, M. E., & Fox, F. J. (2008). Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol. CNS Spectrums, 13(5), pp. 393-403.
Deutsch SI, et al. Current Status of Cannabis Treatment of Multiple Sclerosis With an Illustrative Case Presentation of a Patient With MS, Complex Vocal Tics, Paroxysmal Dystonia, and Marijuana Dependence Treated With Dronabinol. CNS Spectr. 2008;13(5):393-403. PubMed PMID: 18496477.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol. AU - Deutsch,Stephen I, AU - Rosse,Richard B, AU - Connor,Julie M, AU - Burket,Jessica A, AU - Murphy,Mary E, AU - Fox,Fiona J, PY - 2008/5/23/pubmed PY - 2008/8/8/medline PY - 2008/5/23/entrez SP - 393 EP - 403 JF - CNS spectrums JO - CNS Spectr VL - 13 IS - 5 N2 - Pain, spasticity, tremor, spasms, poor sleep quality, and bladder and bowel dysfunction, among other symptoms, contribute significantly to the disability and impaired quality of life of many patients with multiple sclerosis (MS). Motor symptoms referable to the basal ganglia, especially paroxysmal dystonia, occur rarely and contribute to the experience of distress. A substantial percentage of patients with MS report subjective benefit from what is often illicit abuse of extracts of the Cannabis sativa plant; the main cannabinoids include delta-9-tetrahydrocannabinol (delta9-THC) and cannabidiol. Clinical trials of cannabis plant extracts and synthetic delta9-THC provide support for therapeutic benefit on at least some patient self-report measures. An illustrative case is presented of a 52-year-old woman with MS, paroxysmal dystonia, complex vocal tics, and marijuana dependence. The patient was started on an empirical trial of dronabinol, an encapsulated form of synthetic delta9-THC that is usually prescribed as an adjunctive medication for patients undergoing cancer chemotherapy. The patient reported a dramatic reduction of craving and illicit use; she did not experience the "high" on the prescribed medication. She also reported an improvement in the quality of her sleep with diminished awakenings during the night, decreased vocalizations, and the tension associated with their emission, decreased anxiety and a decreased frequency of paroxysmal dystonia. SN - 1092-8529 UR - https://www.unboundmedicine.com/medline/citation/18496477/abstract/ L2 - http://www.diseaseinfosearch.org/result/4969 DB - PRIME DP - Unbound Medicine ER -